The dual glucosedependent insulinotropic peptide andglucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes - Wilson, J M; Nikooienejad, A; Robins, D A (Diabetes Obes Metab, 2020)